PRTN3 and atherosclerosis: Increased prevalence and incidence of subclinical and clinical atherosclerosis in RA, particularly in participants with a disease duration of <5 years.Remission reduces the risk of subclinical and clinical atherosclerosis.T2D, HBP, ACPA positivity, and elevated CRP levels are predictive factors for increased atherosclerosis risk.